The results of a cohort -center randomized study of the modulating effect of Mexidol® in the rehabilitation of patients who have undergone acute cerebral failure

Registered on ClinicalTrials 

A.A. BELKIN, V.A. BELKIN, I.E. VASILCENKO, E.A. PINCHUK
ANO "Clinical Institute of the Brain", Sverdlovsk region, Berezovsky, Russia

Link to the study here

Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2024, Vol. 124, No. 4

Abstract:
Objective of the study. To evaluate the effect of pharmacological modulation of the rehabilitation process with Mexidol as an adjuvant component of rehabilitation treatment of cognitive-emotional disorders in patients who suffered acute cerebral failure (ACF) due to acute cerebrovascular accident or traumatic brain injury. Material and methods. A randomized interventional prospective study was conducted, which consisted of 5 visits. Patients were divided into the main group (MG, n=30, received standard therapy and Mexidol intravenously 500 mg/day for 10 days, followed by the appointment of Mexidol FORTE 250 orally, 1 tablet 3 times a day for 8 weeks) and the comparison group (CG, n=30, received only standard therapy for 66 days). Results. In the MG, a comparable improvement in cognitive functions was observed (p < 0.05 ). Conclusion. A positive modulating effect of Mexidol was demonstrated in accelerating the recovery of tolerance to cognitive loads, improving the psychoemotional background by reducing the symptoms of anxiety and depression, and secondary improving the results of motor rehabilitation in the early recovery period in patients who underwent acute cerebral insufficiency, including with manifestations of PITS. During the study, no adverse events or significant differences in vital functions were recorded, indicating comparable safety of therapy in the MG and CG. Keywords: acute cerebral insufficiency, Mexidol, ethylmethylhydroxypyridine succinate, Beck scale, modulating effect, MexidolNeuro2023.